Doxazosin Mesylate
Product Images NDC 53808-1107

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Doxazosin Mesylate (NDC 53808-1107). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Doh Central Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label Image For 4mg (Doxazosin Mesylate 4mg)

Label Image For 4mg (Doxazosin Mesylate 4mg)
This is a description of a medication called Doxazosin Mesylate in a dosage of 4mg. The medication is sold in a bottle of 30 tablets and is only available with a prescription. It is manufactured by a company called Patheon and packaged by DOH Central Pharmacy in Tallahassee, Florida. The package contains a UPC number which is 006042995519. The lot number is 1214201763 and the expiration date is 121418. There is additional text that is not readable.*
FDA Label Image

Image Of The Chemical Structure Of Doxazosin Mesylate. (Doxazosin 1)

Image Of The Chemical Structure Of Doxazosin Mesylate. (Doxazosin 1)
FDA Label Image

Table 3 Summary Of Effectiveness Data In Placebo-controlled Trials (Doxazosin 2)

Table 3 Summary Of Effectiveness Data In Placebo-controlled Trials (Doxazosin 2)
This is a table presenting the effectiveness data in placebo-controlled trials for the treatment of symptomatic benign prostatic hyperplasia (BPH). The table shows the change in symptom score and maximum flow rate over a certain period for participants treated with a placebo, doxazosin mesylate at different doses. The change in the symptom score was measured using a questionnaire with a range from 0-30, while the maximum flow rate was measured in mL/sec. The table also includes the number of participants, baseline measurement, mean, and standard deviation. Two different studies are presented, one with titration to the maximum dose of 8mg, and another with a fixed dose of 4mg and 8mg.*
FDA Label Image

Image Of Figure 1-study 1 (Doxazosin 3)

Image Of Figure 1-study 1 (Doxazosin 3)
The text describes a chart or graph labeled "Figure 1-Study 1" that shows the mean change in total symptom score from baseline over a period of 14 weeks. The x-axis represents the duration of treatment in weeks, with numbers ranging from 2 to 14. The y-axis represents the mean change in total symptom score, with numbers ranging from 4 to 12.*
FDA Label Image

Image Of Figure 1-study 1 (Doxazosin 4)

Image Of Figure 1-study 1 (Doxazosin 4)
This is a graph that shows the mean increase in maximum urinary flow rate with different durations of treatment. The X-axis displays the durations of the treatment in weeks ranging from 0 to 14, and the Y-axis shows the change in maximum urinary flow rate in mL/sec. The graph compares the mean increase in maximum urinary flow rate from baseline to treatment with or without doxazosin titration. There is a significant increase in maximum urinary flow rate when doxazosin titration was used compared to placebo.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.